Bender Robert & Associates Acquires 400 Shares of Johnson & Johnson (NYSE:JNJ)

Bender Robert & Associates increased its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 7.8% during the third quarter, HoldingsChannel reports. The fund owned 5,507 shares of the company’s stock after buying an additional 400 shares during the quarter. Bender Robert & Associates’ holdings in Johnson & Johnson were worth $900,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of JNJ. Price T Rowe Associates Inc. MD grew its position in Johnson & Johnson by 18.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after acquiring an additional 3,912,430 shares during the last quarter. FMR LLC grew its position in shares of Johnson & Johnson by 20.8% in the 2nd quarter. FMR LLC now owns 18,725,049 shares of the company’s stock valued at $3,323,883,000 after buying an additional 3,229,032 shares during the last quarter. GQG Partners LLC grew its position in shares of Johnson & Johnson by 64.4% in the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock valued at $1,151,931,000 after buying an additional 2,547,378 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in shares of Johnson & Johnson by 52.2% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock valued at $1,083,329,000 after buying an additional 2,093,392 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of Johnson & Johnson by 37.2% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock valued at $1,179,219,000 after buying an additional 1,805,632 shares during the last quarter. Institutional investors own 67.94% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the transaction, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at $6,431,835.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, EVP Jennifer L. Taubert sold 76,923 shares of the company’s stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total value of $13,598,447.94. Following the completion of the transaction, the executive vice president now directly owns 126,456 shares of the company’s stock, valued at $22,354,891.68. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Joseph J. Wolk sold 14,781 shares of the stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the transaction, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at $6,431,835.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 300,750 shares of company stock valued at $52,311,677. Corporate insiders own 0.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on JNJ. Bank of America reduced their price target on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research report on Friday, October 14th. Citigroup boosted their price objective on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research note on Monday, December 12th. Sanford C. Bernstein dropped their price objective on Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Raymond James dropped their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 19th. Finally, StockNews.com assumed coverage on Johnson & Johnson in a research note on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Seven equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $182.42.

Johnson & Johnson Stock Down 0.3 %

JNJ stock opened at $173.43 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. The stock’s 50 day simple moving average is $176.32 and its 200 day simple moving average is $171.55. The company has a market cap of $453.43 billion, a P/E ratio of 24.15, a price-to-earnings-growth ratio of 3.45 and a beta of 0.56. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. The firm had revenue of $23.79 billion during the quarter, compared to analyst estimates of $23.44 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.60 EPS. On average, research analysts expect that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be issued a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.61%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.